CRA International, Inc. (CRAI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance, optimistic guidance, and strategic growth in key areas like energy and life sciences. The increase in dividends and share repurchases is a positive indicator for shareholder returns. Although there are concerns about headcount and long-term visibility, these are outweighed by positive growth metrics and strategic positioning. Given the market cap of $1.2 billion, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Revenue increased by 10.8% year-over-year to $185.9 million. This growth reflects the durability of CRA's business model and was broad-based, with 7 of 11 practices growing year-over-year. Antitrust & Competition Economics, energy, finance, and intellectual property practices posted double-digit revenue growth. North American operations increased revenue by 6.8%, and international operations expanded 30.3% year-over-year, driven by Antitrust & Competition Economics and Life Sciences practices.
Profitability Non-GAAP net income, earnings per diluted share, and EBITDA increased by 12.7%, 16.4%, and 14.6%, respectively, year-over-year. This growth exceeded revenue growth and was driven by strong utilization and overall execution, with quarterly utilization reaching 77%.
Legal and Regulatory Services Revenue Revenue from CRA's legal and regulatory services increased 11.5% year-over-year. This growth was supported by activity in the broader legal market, including increased case filings and court judgments, merger-related activity, and demand for antitrust services.
Management Consulting Services Revenue Revenue increased 8% year-over-year, led by the energy practice and supported by the expansion in the Life Sciences practice. The energy practice contributed through initiatives like developing integrated resource plans and market design analysis, while the Life Sciences practice engaged in strategy for neurological assets and clinical trial design.
Capital Deployment Net cash outlays included $28.1 million to acquire and retain senior talent, $700,000 for capital expenditures, and $7.2 million returned to shareholders through dividends and share repurchases. The company announced a 16% increase in its quarterly cash dividend, supported by business growth and performance.
Consultant Headcount Consultant headcount ended at 968, a 1.0% year-over-year decrease compared to Q3 fiscal 2024, but a 3.3% sequential increase relative to Q2 fiscal 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Antitrust & Competition Economics practice: Established a new high for quarterly revenue, supported high-profile mergers, and advised UnitedHealth Group on a $3.3 billion acquisition of Amedisys.
Intellectual Property practice: Advised on high-stakes litigation and valuation matters, including a patent infringement dispute related to mRNA COVID-19 vaccines, resulting in a $1.25 billion acquisition and $740 million payment to the client.
Energy practice: Supported a major California electric utility in developing its integrated resource plan and advised private capital clients on investments in energy infrastructure and digital infrastructure.
Life Sciences practice: Worked on strategy for a newly acquired portfolio of neurological assets, providing recommendations on clinical trial design and launch sequencing.
Geographic expansion: North American operations increased revenue by 6.8%, while international operations expanded by 30.3%, driven by Antitrust & Competition Economics and Life Sciences practices.
Legal and regulatory services: Revenue increased by 11.5%, supported by double-digit growth in case filings and court judgments.
Utilization rate: Achieved a quarterly utilization rate of 77%, contributing to profitability growth exceeding revenue growth.
Profitability: Non-GAAP net income, earnings per diluted share, and EBITDA increased by 12.7%, 16.4%, and 14.6%, respectively.
Revenue guidance: Raised revenue guidance for fiscal 2025 to $740 million-$748 million, up from $730 million-$745 million.
Dividend increase: Announced a 16% increase in quarterly cash dividend, reflecting confidence in business growth and performance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Uncertain global macroeconomic, business, and political conditions: The company acknowledges that these factors can affect their business and their clients, posing risks to revenue and operational stability.
Regulatory and legal challenges: The company faces risks related to regulatory reviews and legal disputes, as evidenced by their involvement in high-profile cases such as the DOJ's review of UnitedHealth's acquisition and Microsoft's EU competition investigation.
Dependence on key practices and sectors: The company's strong performance is heavily reliant on specific practices like Antitrust & Competition Economics and sectors such as energy and life sciences. Any downturn in these areas could adversely impact overall performance.
High DSO (Days Sales Outstanding): The DSO stood at 115 days, which is relatively high and could indicate potential cash flow challenges or inefficiencies in receivables management.
Debt levels and financial obligations: The company has $95 million in borrowings under its revolving credit facility and net debt of $72.5 million, which could pose financial risks if not managed effectively.
Talent acquisition and retention costs: The company spent $28.1 million in the quarter to acquire and retain senior talent, which represents a significant expenditure and could impact profitability if not balanced with revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: For full year fiscal 2025, CRA expects revenue in the range of $740 million to $748 million on a constant currency basis, an increase from the prior range of $730 million to $745 million.
Non-GAAP EBITDA Margin Guidance: CRA projects a non-GAAP EBITDA margin in the range of 12.6% to 13.0% for fiscal 2025, up from the prior range of 12.3% to 13.0%.
Macroeconomic and Business Conditions: CRA remains cautious about uncertain global macroeconomic, business, and political conditions that could impact its business and clients.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payments: $3.2 million of dividend payments were made during the third quarter of 2025.
Increase in Quarterly Cash Dividend: A 16% increase in the quarterly cash dividend was announced, raising it from $0.49 to $0.57 per common share.
Historical Context of Dividend Growth: The new dividend amount is more than 4 times the size of the first dividend issued in 2016.
Share Repurchase Program: $4.0 million was spent on repurchasing approximately 22,000 shares at an average share price of $185.74 during the third quarter of 2025.
Remaining Share Repurchase Capacity: $10.9 million remains available under the share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is there not a bigger spike in junior consultants quarter-over-quarter, and how sustainable is the current junior-to-senior staff ratio?
A:Paul Maleh explained that CRA continuously evaluates growth opportunities and redeploys resources to areas with higher potential. The current ratio reflects recent lateral hires of Vice Presidents, which temporarily inflates senior headcount. As these hires ramp up, the pyramid structure will be built under them. Headcount growth is expected to align with revenue growth in the medium to long term.
Q:What is driving the strong bill rate revenue growth, and can you confirm the increase in bill rates?
A:Paul Maleh confirmed that bill rates increased by approximately 3% in 2025, primarily due to rate adjustments set at the end of the preceding year. The increase is supported by strong client retention and consistent utilization rates. He suggested that a 2%-4% annual increase in bill rates is a fair assumption for the medium term.
Q:What are the drivers of international growth, particularly in Europe, and how sustainable are they?
A:Paul Maleh highlighted the exceptional performance of the competition practice in Europe, which grew 30% year-over-year. He attributed this to consistent enforcement policies in Europe compared to the U.S., where regulatory stances have been more volatile. The quality of the European team was also emphasized as a key factor.
Q:What is driving the increase in legal and regulatory activity, and how broad-based is this growth?
A:Paul Maleh noted surprising growth in new case filings and court decisions, which is expected to drive consulting demand. Growth is broad-based across practices like Antitrust Competition Economics, intellectual property, Forensic Services, and finance. Seven out of eleven practices grew year-over-year, with four achieving double-digit growth.
Q:Does the company have better visibility into future activity levels compared to previous years?
A:Paul Maleh stated that the company has enjoyed consistent results, providing confidence in future visibility. However, he did not observe a significant increase in long-term project visibility compared to prior years.
Q:Are there specific client verticals showing more activity than others?
A:Paul Maleh mentioned strong demand in the energy sector and a consistent upward trend in the pharmaceutical life sciences space. Litigation practices remain industry-agnostic, and large, complex matters continue to drive consulting demand.
Q:What is the current state of regulatory scrutiny in the U.S. compared to international markets?
A:Paul Maleh observed no decline in U.S. antitrust enforcement, as evidenced by record performance in the Antitrust & Competition Economics practice. Internationally, regulatory scrutiny remains consistently strong, particularly in Europe.
Q:What is the outlook for the life sciences practice?
A:Paul Maleh noted a slight upward trend in the life sciences practice, which is growing mid-single digits year-to-date. While market dynamics support growth, cost disciplines have tempered more pronounced quarter-over-quarter increases.
Q:What is driving the growth in the intellectual property practice, and how sustainable is it?
A:Paul Maleh highlighted strong cross-practice collaborations and the practice's reputation as a go-to provider. Demand drivers like AI and complex matters are expected to sustain growth.
Q:What is contributing to the strong hiring of Vice Presidents in 2025?
A:Paul Maleh attributed the hiring success to CRA's value proposition, market success, and the demonstrated success of new hires. The company is being selective but has added approximately 20 new Vice Presidents in 2025.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the sustainability of certain trends, such as the long-term visibility of project inflows and the exact future growth trajectory of the life sciences practice. Additionally, while they acknowledged strong hiring and regulatory activity, they did not provide granular data or specific examples to substantiate these claims.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alzheimer disease
Amedisys DOJ
Antitrust Competition
COVID vaccine
CRA client
CRA competition
Competition Economics
Executive VP
Life Sciences
Microsoft
Sciences practice
UnitedHealth
acquisition
asset
capital dividend
commitment
deal
design
digit
dispute
expertise
finance
infrastructure
launch
merger activity
party
practice CRA
property practice
quality
repurchase
review
settlement
stake litigation
transfer pricing
trial
utility
CRAI Transcript
CRA International, Inc. (CRAI) Q1 2026 Earnings Call Transcript
Positive5-9
The earnings call reflects strong financial performance with record revenue and profitability, particularly in the Life Sciences and M&A sectors. Although there are increased costs and a restructuring charge, the company maintains a positive outlook with strong demand and utilization rates. The Q&A reveals optimism about talent acquisition and growth despite some general responses. Given the market cap, this translates to a positive stock price movement, likely between 2% to 8%.
CRA International, Inc. (CRAI) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals record-high revenue and strong performance across various practices, with optimistic guidance for fiscal 2026. The Q&A section supports this with positive sentiment towards revenue growth, AI initiatives, and shareholder returns. Despite flat headcount growth, future increases are expected, aligning with revenue growth. The company's active share repurchase plan indicates confidence in undervaluation. Overall, strong financial metrics, optimistic guidance, and strategic initiatives suggest a positive stock price movement.
CRA International, Inc. (CRAI) Presents at UBS Global Technology and AI Conference 2025 Transcript
Neutral12-1
CRA International, Inc. (CRAI) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call summary and Q&A indicate strong financial performance, optimistic guidance, and strategic growth in key areas like energy and life sciences. The increase in dividends and share repurchases is a positive indicator for shareholder returns. Although there are concerns about headcount and long-term visibility, these are outweighed by positive growth metrics and strategic positioning. Given the market cap of $1.2 billion, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
CRAI Slides
CRAI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
